MicroRNA Dynamics in Type 1 Diabetes Pathogenesis

Type 1 diabetes arises through autoimmune destruction of insulin‐producing pancreatic β‐cells. MicroRNAs (miRNAs) have emerged as critical regulators at the interface of immune activation and β‐cell function, modulating gene expression post‐transcriptionally. Dysregulated miRNA expression contributes to both initiation and progression of islet inflammation (insulitis) by influencing antigen presentation, T‐cell differentiation and pro‐inflammatory cytokine release. Within pancreatic islets, specific miRNAs adjust β‐cell stress responses, insulin synthesis and secretion, and cell survival pathways. Circulating miRNAs mirror tissue‐level alterations, offering non‐invasive biomarkers for disease staging and risk stratification. Integration of miRNA profiling, functional network analyses and mechanistic studies has elucidated signalling cascades—such as NF-κB, STAT3 and TGF-β—that underlie immune‐mediated β‐cell damage. Understanding temporal changes in miRNA landscapes holds promise for refining early detection, monitoring therapeutic interventions and identifying novel targets to preserve residual β‐cell function globally.

Research from Nature Portfolio

Recent studies have profiled circulating miRNA signatures in adults with long‐standing type 1 diabetes, identifying elevated levels of hsa-miR-1-3p that correlate with glycated haemoglobin and vascular gene networks, suggesting its utility as a prognostic biomarker for cardiovascular comorbidities. Foundational mechanistic work in human regulatory T cells from pancreatic lymph nodes revealed that upregulation of miR-125a-5p reduces CCR2 expression, thereby impairing Treg migration to inflamed islets and highlighting a targetable axis for enhancing immune regulation. Seminal investigations have also demonstrated that miR-30a functions as an inflammation-buffering factor by targeting interleukin 1α and modulating the NF-κB signalling cascade in islet and immune cells, pointing to its potential as a therapeutic biomarker and anti-inflammatory agent in early diabetes intervention.

MicroRNA Dynamics in Type 1 Diabetes Pathogenesis publication trend

The graph below shows the total number of articles in microrna dynamics in type 1 diabetes pathogenesis across all publications each year (not limited to Nature Index journals).

Technical terms

MicroRNA (miRNA): Small non-coding RNA molecules that regulate gene expression by binding to target messenger RNA (mRNA) and inhibiting translation or promoting degradation.

Pancreatic β-cell: Insulin-secreting cell located in the islets of Langerhans, whose autoimmune destruction underpins type 1 diabetes.

Regulatory T cell (Treg): Subset of T lymphocytes that maintain immune tolerance by suppressing autoreactive immune responses.

Insulitis: Inflammatory infiltration of pancreatic islets characterised by immune cell accumulation and cytokine release.

Nuclear factor kappa B (NF-κB): Transcription factor that regulates genes involved in immune responses and cell survival.

TGF-β signalling: Pathway mediated by transforming growth factor-beta cytokines that modulates immune regulation and cell proliferation.

References

1. Exploratory miRNA profiling from serum and bone tissue of mice with T1D-induced bone loss. Frontiers in Endocrinology (2024).
2. Circulating miRNA expression in long-standing type 1 diabetes mellitus. Scientific Reports (2023).
3. Importance of Studying Non-Coding RNA in Children and Adolescents with Type 1 Diabetes. Biomedicines (2024).
4. Regulatory T-cells from pancreatic lymphnodes of patients with type-1 diabetes express increased levels of microRNA miR-125a-5p that limits CCR2 expression. Scientific Reports (2017).
5. MiR-30a targets IL-1α and regulates islet functions as an inflammation buffer and response factor. Scientific Reports (2017).